---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000037"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:14:50.294034+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q1 revenue up 38% to $162M; GAAP EPS $0.29; reiterates 2023 guidance

## Summary
- Revenue of $162.1M (+38% YoY); royalty revenue $99.6M (+43% YoY).
- GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.47 (flat YoY).
- Q1 net income $39.6M vs $60.1M in Q1 2022; EBITDA $74.3M.
- Reiterates 2023 guidance: total revenue $815-845M, non-GAAP EPS $2.50-$2.65.
- Repurchased 4.2M shares for $150M in Q1; $275.6M cash end of quarter.

## SEC filing metadata
- accession: 0001159036-23-000037
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/0001159036-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/halo-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000037
- JSON: https://secwatch.observer/filing/0001159036-23-000037.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000037.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: revenue $162.1 million, net income $39.6 million, EPS $0.29. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $162.1 million
  - Net income: $39.6 million
  - EPS: $0.29
  - Guidance: reaffirmed
  - Result: reported results
  source text: any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue Increased 43% YOY to $99.6 million Reiterating 2023 Revenue Guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/0001159036-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.